Journal article

The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications

S Moylan, M Maes, NR Wray, M Berk

Molecular Psychiatry | NATURE PUBLISHING GROUP | Published : 2013

University of Melbourne Researchers

Grants

Funding Acknowledgements

Dr S Moylan, Professor NR Wray and Professor M Maes declare no conflict of interest. Professor M Berk has received Grant/Research Support from Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma and Servier, has been a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvayand Wyeth, and served as a consultant to Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck and Servier.